Zdrehus, R.; Delcea, C.; Mocan, L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics2024, 16, 410.
Zdrehus, R.; Delcea, C.; Mocan, L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics 2024, 16, 410.
Zdrehus, R.; Delcea, C.; Mocan, L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics2024, 16, 410.
Zdrehus, R.; Delcea, C.; Mocan, L. Role of Biofunctionalized Nanoparticles in Digestive Cancer Vaccine Development. Pharmaceutics 2024, 16, 410.
Abstract
Nanotechnology has provided an opportunity for unparalleled development of the treatment of various severe diseases. The unique properties of nanoparticles offer a promising strategy in enhancing antitumor immunity by enhancing immunogenicity and presentation of tumor autoantigens for cancer immunotherapy. Polymeric, liposomal, carbon or silica-based nanoparticles are among those with major immunomodulatory roles in various cancer treatments. Cancer vaccines, in particular digestive cancer vaccines have been researched and developed on nanotechnological platforms. Due to their safety, controlled release, targeting of dendritic cells(DCs) and improved antigen uptake, as well as enhanced immunogenicity, nanoparticles have been used as carriers, as adjuvants for increased effect at the tumor level, for their immunomodulating effect, or for targeting tumor microenvironment, increasing tumor immunogenicity and reducing tumor inflamatory response. This review looks at digestive cancer vaccines developed on nanoparticle platforms and the impact nanoparticles have on the effects of these vaccines.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.